Additionally, inhibiting PD-L1 can induce a decrease in M2 markers (IL-10 and Arg-1) and an increase in M1 markers (IL-12 and TNF-α), suggesting an enhanced anti-tumor immune response [48]. The gene discussed is CD274; the disease is neoplasm.